Exclusive: Typewriter raises $56M for jumping-gene tech, in vivo CAR-T

Typewriter Therapeutics raises $56M Series A to build RNA-based jumping-gene therapies for in vivo CAR-T and genetic liver disease.

Raccontata daendpoints.news